Cryomedical Sciences, Inc. Announces Filing of Complaint by Endocare, Inc.

ROCKVILLE, Md.--(BUSINESS WIRE)--March 26, 1999--

Complaint Alleges Libel, Slander, False Advertising,

and Unfair Business Practices as They Relate to

Cryomedical Press Releases Regarding Dangers of Using High

Pressure Cryosurgery Systems

Cryomedical Sciences, Inc., (OTC BB:CMSI)(CMSI) announced today that one of its competitors, Endocare, Inc. had filed a complaint alleging that CMSI, its CEO, and Senior Vice President are liable for statements made in press releases that the Company issued in the past in which the dangers of using high pressure cryosurgical devices were delineated.

The complaint alleges that the Company had engaged in a pattern of representing that Endocare's devices are unsafe and that Endocare's devices have a history of putting patients in danger. The Company and its officers deny any culpability in regard to the charges and intend to vigorously pursue and defend the case.

Richard J. Reinhart, Ph.D., President and CEO of CMSI stated, "In each of May, 1997 and January, 1999, without mentioning the name of the company involved, CMSI the leading manufacturer of low-pressure cryosurgical systems in the United States, and to a lesser extent a manufacturer of high-pressure cryosurgical systems, put out a press release relating to a clinical incident in which a cryosurgical device utilizing a high-pressure cryogen source resulted in harm to a patient. Having the largest installed customer base of cryosurgical instrumentation in the United States, the Company felt the need to advise physicians of the need for caution when using the type of instrumentation that utilizes high pressure gases as cryogens, and to reassure its customers and potential customers of the safety attributes of low pressure cryosurgical systems. The press release reported that CMSI was making available safety refresher courses to users of all cryosurgical instrumentation and that it was available for consultations regarding safety matters that should be considered when using high-pressure systems.

The Company makes no apologies for its actions, which it deems to be in the best interest of the industry as a whole and it medical community at large. We encourage other companies which sell cryosurgical instrumentation to assist and promote patient safety in the education and training of the medical community regarding attributes and potential problems associated with the use of various types of cryosurgical instrumentation. Based upon the recent Health Care Finance Administration (HCFA) announcement to cover cryosurgery of the prostate for patients with localized prostate cancer, CMSI wants to work with competitors, physicians, patient advocacy groups, etc. to pursue the long-term goal of making cryosurgery, which is patient friendly, the treatment of choice for patients with localized prostate cancer."

Cryomedical Sciences, Inc. is the leader in the field of cryosurgical devices that ablate unwanted tissue in minimally invasive procedures. The Company's CMSI AccuProbe(R) System has been cleared for marketing in the U.S. in the fields of urology, oncology, general surgery, gynecology and neurology, among others. BioLife Technologies, Inc. is a wholly owned subsidiary of CMSI formed in March 1998 for the purpose of commercializing the CMSI preservative solutions.

This release contains forward-looking statements, including but not limited to technological competitive advantages. The actual results that the Company achieves may differ materially from any forward-looking statements due to many factors, including acceptance of the Company's products, the impact of competitive products and pricing, market conditions, government regulations, and the risks and uncertainties discussed in the Company's Annual Report on Form 10-KSB and other reports filed with the Securities and Exchange Commission. Such risk factors include, but are not limited to, operating history of the Company with a history of losses; fluctuations in the Company's order levels; uncertainty of product development and the risks related to clinical trials; the rapid pace of technological change in the Company's industry; and uncertainty relating to third party reimbursement and regulatory matters.